

EMA/3693/2016

European Medicines Agency decision

P/0016/2016

of 29 January 2016

on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (EMEA-000727-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0016/2016

of 29 January 2016

on the acceptance of a modification of an agreed paediatric investigation plan for bosutinib (EMA-000727-PIP01-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/170/2010 issued on 3 September 2010,

Having regard to the application submitted by Pfizer Limited on 18 September 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 December 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral and to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for bosutinib, age appropriate oral formulation, tablet, capsule, oral use, including changes to the deferral, and to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Pfizer Limited, Ramsgate Road, CT13 9NJ – Sandwich, United Kingdom.

Done at London, 29 January 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/642653/2015
London, 11 December 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000727-PIP01-09-M01

Scope of the application

Active substance(s):

Bosutinib

Condition(s):

Treatment of chronic myeloid leukaemia (CML)

Pharmaceutical form(s):

Capsule

Tablet

Age appropriate oral formulation

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Pfizer Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Limited submitted to the European Medicines Agency on 18 September 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/170/2010 issued on 3 September 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral and to the waiver.

The procedure started on 13 October 2015.



Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral and to the waiver in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic myeloid leukaemia (CML)

The waiver applies to:

- The paediatric population from birth to less than 1 year of age;
- for capsules, tablets and age appropriate oral formulation;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of chronic myeloid leukaemia (CML)

2.1.1. Indication(s) targeted by the PIP

- Treatment of chronic phase CML in children and adolescents (from 1 to less than 18 years of age);
- Treatment of chronic, accelerated or blast phase CML in children and adolescents with resistance or intolerance to prior therapy including imatinib.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

- Capsule 25 mg and 50 mg with age-appropriate size
- Tablet 100 mg and 500 mg with age-appropriate size
- Age appropriate oral formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of age appropriate oral formulation and strength.
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 2 Study 2 was removed.

		Study 3 Bioequivalence study with bosutinib in adults with paediatric age- appropriate formulations. Study 4 Two-phase study, a 6+4 dose escalation phase to determine a recommended phase 2 dose based on tolerability and PK of bosutinib and an open-label, non-controlled phase to evaluate anti-leukemic activity (determined by central laboratory analysis of cytogenetic and molecular response data), safety, tolerability, and PK of bosutinib.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Measures to address long term follow-up of potential safety issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	March 2020
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic myeloid leukaemia (CML)

Authorised indication(s):

- Bosulif is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use